Earnings Ahead

SRPT - Sarepta Therapeutics Inc.

106.4 -1.88 -1.74

Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc.

About

Profile

Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

SRPT



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M
  • Sarepta Therapeutics Q3 2023 Earnings Preview
  • Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more
  • Sarepta in selloff after late-stage setback for Duchenne candidate
  • 5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more
  • Sarepta Phase 3 study for DMD drug fails to meet primary endpoint
  • Mizuho doesn't see Sarepta price decline connected to EMBARK study
  • Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M
  • Sarepta Therapeutics Q2 2023 Earnings Preview
  • Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023
  • Catalyst Watch: CPI, major bank earnings, Amazon Prime Day and CAVA ratings
  • Sarepta raises $102M from selling priority review voucher
  • Sarepta down 9% as Duchenne treatment gets narrow population approval
  • Sarepta Duchenne treatment wins FDA nod, but with smaller population (update)
  • Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy
  • Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event
  • Hot Stocks: ANF, URBN and PANW rise on earnings; A, XPEV fall on weak outlooks; OCGN slides
  • Sarepta says FDA needs more time to review muscular dystrophy drug
  • Billions of dollars at stake as FDA shortcut allows half-proven drugs - report
  • Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Earnings History

Date EPS / Forecast Revenue / Forecast
October 27, 2021 - / -1.83 - / 171.36M
August 4, 2021 -1.02 / -1.3 164.09M / 167.07M
May 5, 2021 -2.1 / -1.83 146.93M / 145.81M Beat!
March 1, 2021 -2.4 / -1.8 145.14M / 150.38M
November 5, 2020 -2.5 / -1.71 143.92M / 137.76M Beat!
August 5, 2020 -1.93 / -1.72 137.36M / 116.29M Beat!
May 6, 2020 -0.23 / -1.92 113.67M / 116.49M
February 26, 2020 -3.16 / -1.81 100.11M / 98.8M Beat!
November 7, 2019 -1.7 / -1.35 99.04M / 98.48M Beat!
August 7, 2019 -3.74 / -1.07 94.67M / 91.05M Beat!
May 8, 2019 -1.07 / -1.61 87.01M / 86.6M Beat!
February 27, 2019 -2.05 / -1.02 84.42M / 84.92M
October 24, 2018 -1.15 / -0.78 78.49M / 78.75M
August 8, 2018 -1.67 / -0.84 73.53M / 71.4M Beat!
May 3, 2018 -0.55 / -0.32 64.6M / 65.09M
February 26, 2018 - / -0.32 - / 55.57M
October 25, 2017 -0.76 / -0.85 45.95M / 40.77M Beat!
July 19, 2017 -0.46 / -0.77 35.01M / 22.38M Beat!
April 27, 2017 -0.71 / -0.81 16.34M / - Beat!
February 28, 2017 -0.71 / -0.45 5.42M / 46.83M
October 27, 2016 -1.18 / -0.52 - / 3.08M
Date Price Open High Low Vol Change
May 23 127.13 128.12
129.84
125.5
848K -0.91%
May 22 128.3 128.93
130.94
127.66
723K -0.64%
May 21 129.12 130.11
131.02
127.68
748K -1.31%
May 20 130.83 132.15
132.15
128.75
780K -0.42%
May 17 131.38 132.88
133.12
129.5
849K -1.02%
 
May 16 132.74 132.04
133.06
129.56
1.0M 0.18%
May 15 132.5 134
134.71
132.1
763K -0.12%
May 14 132.66 133.55
134.34
130.89
1.2M 0.73%
May 13 131.7 132.25
133.55
129.78
634K -0.09%
May 10 131.82 132.87
132.87
129.44
736K -0.36%
May 9 132.3 133.22
133.39
129.49
1.3M -0.21%
May 8 132.58 137.14
137.14
129.45
1.6M -2.54%
May 7 136.04 135.1
146.68
132.3
2.0M 0.74%
May 6 135.04 133.6
135.16
132.62
823K 1.03%
May 3 133.66 132.55
134.46
131.16
1.2M 2.32%
May 2 130.63 140
142.79
130.05
2.2M -0.21%
May 1 130.9 127.06
131.61
127
1.2M 3.35%
Apr 30 126.66 128.65
129.7
126.53
1.1M -1.66%
Apr 29 128.8 129.02
131.8
127.47
1.0M 0.02%
Apr 26 128.77 127.53
131.46
125.62
1.2M 1.08%
Apr 25 127.39 123
130.61
121.8
1.7M 2.53%
Apr 24 124.25 117.66
125.13
117.21
1.5M 6.09%
Apr 23 117.12 117.5
119.91
117.06
569K 0.14%
Apr 22 116.96 116.63
118.43
114.48
889K 1.16%
Apr 19 115.62 116.55
117.74
114.37
641K -0.8%
Apr 18 116.55 117.55
118.9
115.79
499K -1.14%
Apr 17 117.89 117
119.08
115.93
546K 0.51%
Apr 16 117.29 117.6
118.69
116.94
593K -0.86%
Apr 15 118.31 122.18
122.99
117.78
860K -3.71%
Apr 12 122.87 124.17
124.82
121.49
656K -1.27%
Apr 11 124.45 127.28
127.49
123.4
618K -1.47%
Apr 10 126.31 124.13
126.47
123.87
523K -0.53%
Apr 9 126.98 126.46
127.41
126.07
286K 0.47%
Apr 8 126.39 126.17
126.68
124.37
559K 0.25%
Apr 5 126.08 125.43
127.64
123.85
304K 0.23%
Apr 4 125.79 127.22
128.23
124.87
747K -0.89%
Apr 3 126.92 126.07
128.6
125.17
851K -0.06%
Apr 2 127 127.68
128.8
125.8
519K -1.09%
Apr 1 128.4 129.38
129.38
126.11
858K -0.82%
Mar 28 129.46 131.16
131.16
127.83
812K -0.59%
Mar 27 130.23 129.25
130.32
127.36
593K 1.54%
Mar 26 128.25 129.83
129.97
128
530K 0.24%
Mar 25 127.94 127
128.95
126
396K 0.31%
Mar 22 127.54 125.14
128.19
124.75
628K 2.08%
Mar 21 124.94 126.98
128.43
124.27
458K -0.9%
Mar 20 126.08 124.37
126.11
122.72
552K 1.63%
Mar 19 124.06 123.8
125.6
122.65
811K 0.07%
Mar 18 123.97 123.72
125.41
122.33
523K 0.75%
Mar 15 123.05 123.49
125.25
121.6
1.2M -0.57%
Mar 14 123.76 121.17
125
120.58
644K 1.48%
Mar 13 121.96 122.36
122.9
121.08
685K -0.03%
Mar 12 122 122.25
123.25
120.99
732K 0.35%
Mar 11 121.58 124.03
125.43
121.04
929K -2.24%
Mar 8 124.37 120.97
125.5
120.09
1.3M 2.97%
Mar 7 120.78 120.41
122.67
119.64
958K 0.39%
Mar 6 120.31 122.77
123.59
119.86
879K -2.07%
Mar 5 122.85 122.09
124.24
121.08
998K -0.83%
Mar 4 123.88 128.67
128.67
123.31
851K -3.72%
Mar 1 128.67 127.18
130.59
124.9
1.7M 0.60%
Feb 29 127.9 136.67
138
127.31
2.1M 0%